GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
I

Invech Holdings IVHI · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.02

—

Close of 2 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Invech Holdings

From its filings with the US Securities and Exchange Commission

SEC filings

Invech Holdings is based in Las Vegas, Nevada and is incorporated in Nevada. Its shares trade on OTC under the ticker IVHI. The SEC classifies its business as management consulting services. In the fiscal year to 31 December 2025, it reported revenue of $0 and a net loss of $58,018. At that date it held total assets of $1,500 and shareholders' equity of −$62,149.

Read the filing on SEC.gov ↗

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
14 Jan 2005
Head office
7963 BROADWING DRIVE, LAS VEGAS, NV, 89084
Incorporated in
NV
Classification
Services-Management Consulting Services
Filer status
Non-accelerated filer<br>Smaller reporting company

Leadership

Pay as last reported

  • Ms. Rhonda KeaveneyChief Executive Officer, Chief Financial Officer, Director, since 2023

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Company is in the Health Care sector with a focus on Pharmaceuticals.
  • Headquartered in Wuhan, China, with a clear country and city location.
  • IPO date is provided as 2005-01-14, indicating a long-standing presence.

Weaknesses

  • Source description is untrusted and contradicts the provided sector and industry information.
  • No specific financial data or performance metrics are provided.
  • The company's actual business focus appears to be regulatory drafting and consulting, not Pharmaceuticals.

Opportunities

  • Potential to leverage the Health Care sector growth in China.
  • Possible expansion into pharmaceuticals if the source description is inaccurate.
  • Use of IPO date to attract long-term investors interested in established companies.

Threats

  • Contradictory information about the company's business focus may confuse investors.
  • Untrusted source description could damage credibility and trust.
  • Lack of financial data makes it difficult to assess company performance.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.